Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety conce...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yue, Yang, Yanbo, Wang, Zilan, Jiang, Fan, Chen, Zhouqing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919188/
https://www.ncbi.nlm.nih.gov/pubmed/33658933
http://dx.doi.org/10.3389/fphar.2020.589146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919188/
https://www.ncbi.nlm.nih.gov/pubmed/33658933
http://dx.doi.org/10.3389/fphar.2020.589146

Ejemplares similares